- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Maze Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Maze Therapeutics, Inc.: Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | 40 | GlobeNewswire (Europe) | MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling... ► Artikel lesen | |
| 23.07. | H.C. Wainwright startet Coverage für Maze Therapeutics mit "Buy"-Rating und Kursziel von 34 US-Dollar | 2 | Investing.com Deutsch | ||
| 23.07. | H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating | - | Investing.com | ||
| 14.05. | Maze Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Maze Therapeutics, Inc.: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones | 132 | GlobeNewswire (Europe) | MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong... ► Artikel lesen | |
| 31.03. | Maze Therapeutics GAAP EPS of -$18.32 | 3 | Seeking Alpha | ||
| 31.03. | Maze Therapeutics, Inc.: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights | 245 | GlobeNewswire (Europe) | MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised... ► Artikel lesen | |
| 31.03. | Maze Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Maze Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.02. | Maze Therapeutics receives positive ratings following recent IPO | 1 | Investing.com | ||
| 25.02. | Leerink starts Maze Therapeutics stock with Outperform rating | 1 | Investing.com | ||
| 25.02. | Cowen initiates Maze Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 25.02. | Guggenheim sets $19 target on Maze Therapeutics stock | 1 | Investing.com | ||
| 25.02. | JPMorgan sets Maze Therapeutics stock to Overweight with $30 target | 2 | Investing.com | ||
| 07.02. | Maze Therapeutics, Inc.: Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease | 267 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop... ► Artikel lesen | |
| 31.01. | Maze Therapeutics Prices Upsized IPO Of 8.75 Mln Shares At $16.00/shr | 799 | AFX News | WASHINGTON (dpa-AFX) - Maze Therapeutics Inc. (MAZE) announced that it has priced its upsized initial public
offering of 8.75 million shares of its common stock at a public offering price... ► Artikel lesen | |
| 31.01. | Maze Therapeutics, Inc.: Maze Therapeutics Announces Pricing of Upsized Initial Public Offering | 149 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRINITY BIOTECH | 1,930 | 0,00 % | Trinity Biotech plc: Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara Preeclampsia Testing Service | DUBLIN, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,635 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| EVOTEC | 6,396 | -1,75 % | Evotec-Aktie: Die Zukunft zählt! | Die Evotec-Aktie startete mit einem deutlichen Kursanstieg in den Handel, verlor dann jedoch wieder; aktuell steht sie bei 6,70 €. Ursache für den Anstieg ist die Bekanntgabe der Zahlen für das erste... ► Artikel lesen | |
| 180 LIFE SCIENCES | 7,710 | 0,00 % | 180 Life Sciences setzt auf Ethereum - Milliardenwechsel in Geschäftsstrategie | Die 180 Life Sciences Corp. (Börsenkürzel: ATNF) hat bekanntgegeben, inzwischen 82.186 Ether-Token zu halten - ein Bestand, der zum 11. August 2025 rund 349 Millionen US-Dollar wert war. Der durchschnittliche... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,090 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,450 | 0,00 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| CG ONCOLOGY | 25,980 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates | - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,640 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 14,480 | 0,00 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| HUMACYTE | 1,880 | 0,00 % | Humacyte: Benchmark bestätigt Kaufempfehlung trotz Umsatzverfehlung | ||
| ADMA BIOLOGICS | 16,970 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 42,145 | +0,20 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| VALNEVA | 4,574 | +4,19 % | Rheinmetall: Schwach, aber... - Bayer, Commerzbank, Deutz, ThyssenKrupp und Valneva im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| COGNITION THERAPEUTICS | 1,660 | 0,00 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease | - Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 15,980 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |
Das Unternehmen MAZE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 13,325 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAZE THERAPEUTICS INC finden Sie auf Wallstreet Online.